US4510337086 - Common Stock
IBIO INC
NYSEARCA:IBIO (4/26/2024, 7:04:00 PM)
1.76
+0.04 (+2.33%)
Ibio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Bryan, Texas and currently employs 26 full-time employees. The company went IPO on 2008-08-18. iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The firm develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. The company is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, CCR8 and PD-1 Agonist. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
IBIO INC
8800 HSC Pkwy
Bryan TEXAS 77807
P: 19794460027
CEO: Thomas F. Isett
Employees: 26
Website: https://www.ibioinc.com/
The healthcare industry is one of the most potent yet also one of the most competitive. This has short sellers out for blood.
Canada Goose layoffs are in the news Wednesday as the luxury apparel company prepares to cut 17% of its corporate employees.
Rent the Runway stock is falling on Wednesday after the company announced a one-for-20 reverse split for its shares coming in April.
IBIO stock is soaring after the firm announced that it would launch a partnership based on AI and obesity treatments.
– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative...
– Purchase price of $2.85 represents a premium of 148+% to last close –
Here you can normally see the latest stock twits on IBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: